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Abstract
Background—Current guidelines only recommend the use of an implantable cardioverter 
defibrillator (ICD) in patients with dilated cardiomyopathy (DCM) for the primary prevention of 
sudden cardiac death (SCD) in those with a left ventricular ejection fraction (LVEF)<35%. 
However, registries of out-of-hospital cardiac arrests demonstrate that 70-80% of such patients 
have a LVEF>35%. Patients with a LVEF>35% also have low competing risks of death from 
non-sudden causes. Therefore, those at high-risk of SCD may gain longevity from successful 
ICD therapy. We investigated whether late gadolinium enhancement cardiovascular magnetic 
resonance (LGE-CMR) identified patients with DCM without severe LV systolic dysfunction at 
high-risk of SCD.
Methods—We prospectively investigated the association between mid-wall late gadolinium 
enhancement (LGE) and the pre-specified primary composite outcome of SCD or aborted SCD 
DPRQJVWFRQVHFXWLYHUHIHUUDOVZLWK'&0DQGD/9()WRRXUFHQWer between January 2000 
and December 2011, who did not have a pre-existing indication for ICD implantation.
Results—Of 399 patients (145 women, median age 50 years, median LVEF 50%, 25.3% with 
LGE) followed for a median of 4.6 years, 18 of 101 (17.8%) patients with LGE reached the pre-
specified end-point, compared to 7 of 298 (2.3%) without (HR 9.2; 95% CI 3.9-21.8; p<0.0001). 
Nine patients (8.9%) with LGE compared to 6 (2.0%) without (HR 4.9; 95% CI 1.8-13.5;
p=0.002) died suddenly, whilst 10 patients (9.9%) with LGE compared to 1 patient (0.3%)
without (HR 34.8; 95% CI 4.6-266.6; p<0.001) had aborted SCD. Following adjustment, LGE
predicted the composite end-point (HR 9.3; 95% CI 3.9-22.3; p<0.0001), SCD (HR 4.8; 95% CI 
1.7-13.8; p=0.003) and aborted SCD (HR 35.9; 95% CI 4.8-271.4; p<0.001). Estimated hazard 
ratios for the primary end-point for patients with a LGE extent of 0-2.5%, 2.5-5% and >5% 
compared to those without LGE were 10.6 (95%CI 3.9-29.4), 4.9 (95% CI 1.3-18.9) and 11.8 
(95% CI 4.3-32.3) respectively.
Conclusions—Mid-wall LGE identifies a group of patiHQWVZLWK'&0DQG/9()DW
increased risk of SCD and low-risk of non-sudden death who may benefit from ICD 
implantation.
Clinical Trial Registration— https://clinicaltrials.gov/ Identifier: NCT00930735 
Key-Words: dilated cardiomyopathy; sudden cardiac death; late gadolinium enhancement; 
cardiovascular magnetic resonance imaging; implantable cardioverter-defibrillator; mid-wall
fibrosis
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Clinical Perspective
What is new? 
x This study demonstrates that mid-wall late gadolinium enhancement (LGE) identifies 
patients with dilated cardiomyopathy (DCM) and mild and moderate reductions in left 
ventricular ejection fraction (LVEF) at high-risk of sudden cardiac death (SCD). 
What are the clinical implications? 
x Patients with DCM and mid-wall LGE and mild or moderate reductions in LVEF should 
be recognised as having a high-risk of SCD. 
x This is important because these patients are not currently offered ICDs for the primary
prevention of SCD, on the basis of guideline recommendations.
x Due to low competing risks of death from non-sudden causes, it is possible that these 
patients will benefit from ICD implantation.
x Randomized trials investigating the benefit of pharmacological therapies and ICD 
implantation in patients with LGE and less severe reduction in LVEF are now required. 
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Introduction
Guidelines only recommend the use of implantable cardioverter defibrillators (ICDs) in patients 
with dilated cardiomyopathy (DCM) for the primary prevention of sudden cardiac death (SCD) 
in those with a left ventricular ejection fraction (LVEF) <35%.1, 2 However, registries of out-of-
hospital cardiac arrests demonstrate that 70-80% of such patients have a LVEF >35% indicating 
that, in fact, the major burden of SCD occurs in patients with less severe degrees of left 
ventricular (LV) impairment.3, 4 The need to identify the sub-group of patients with mild and 
moderate reductions in LVEF at high risk of SCD has been highlighted by guidelines and 
statements from the American Heart Association, American College of Cardiology, European 
Society of Cardiology and Heart Rhythm Societies.2, 5-7 Importantly, such patients are likely to 
have a lower risk of death from competing causes and fewer symptoms compared to patients 
with lower LVEF and may potentially have more to gain in terms of quality-adjusted life years 
from successful ICD therapy. This is particularly pertinent following the DANISH trial, which 
highlighted the importance of selecting patients with a low risk of death from other causes.8
Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) has shown that 
approximately 30% of patients with DCM have mid-wall LGE which represents replacement
fibrosis and that this provides incremental prognostic information to LVEF.9-17 Whether mid-
wall LGE also identifies a high-risk of SCD in patients with DCM and less severe reductions in 
LVEF, who might consequently benefit from an ICD, is unknown.18  Accordingly, we 
investigated whether mid-wall LGE is associated with SCD and aborted SCD in a large cohort of 
FRQVHFXWLYHSDWLHQWVZLWK'&0DQG/9()$/9()FXW-RIIRIRQ&05ZDVFKRVHQ
as this approximates to an LVEF of 35% on echocardiography, the current arbiter of primary 
prevention ICD implantation.1, 2, 19-21
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Methods
Patients seen in our cardiomyopathy service or referred for CMR assessment between November 
2000 and December 2011 with '&0DQGD/9()were prospectively identified at the time 
of the scan and entered in a registry.  Of 399 patients, 193 were included in a previous study of 
‘all-comers’ with DCM investigating LGE and all-cause mortality regardless of LVEF.9 These 
patients underwent extended follow-up for the current stand-alone, focused investigation in this 
select population. All participants provided informed consent and the study was approved by the 
National Research Ethics Service. The inclusion criterion was a diagnosis of DCM confirmed 
using the World Health Organization/International Society and Federation of Cardiology criteria, 
on the basis of an elevated left ventricular end-diastolic volume indexed to body surface area 
(LVEDVi) and reduced LVEF, compared to published age- and gender-specific reference 
values.22 Exclusion criteria are listed in Figure 1 and included the presence of significant 
coronary artery disease (CAD), defined as a stenosis of greater than 50% in a major coronary 
artery, infiltrative disease or valvular cardiomyopathy.  To ensure patients with ischemic 
aetiologies were not included those with infarct patterns of LGE were also excluded.23 Patients 
with a history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope 
were excluded given a potential pre-existing secondary prevention indication for ICD 
implantation. These patients have been included in an additional analysis in the Supplemental 
Material (Supplemental Figure 1). No patients had a pre-existing indication for ICD 
implantation on the basis of primary prevention of SCD. 
 CMR was carried out on 1.5 Tesla scanners (Sonata/Avanto, Siemens, Erlangen, 
Germany), using a standardized protocol (Supplemental Material). The presence and location of 
mid-wall LGE were assessed by two independent Society of Cardiovascular Magnetic 
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Resonance level 3 accredited operators blinded to clinical outcomes, with a third providing 
adjudication if necessary (MA, CI, FA). LGE was considered present if mid-myocardial or sub-
epicardial and visible in two phase-encoding directions and two orthogonal planes. The mass of 
LGE (grams) was quantified by a blinded operator using the full-width at half-maximum 
technique (CMR42, Circle Cardiovascular Imaging Inc, Calgary, Canada) and indexed as a 
percentage of left ventricular (LV) mass (MA, CI).
 The pre-specified primary end-point was a composite of SCD or aborted SCD. SCD was 
defined as unexpected death either within 1 hour of the onset of cardiac symptoms in the absence 
of progressive cardiac deterioration; during sleep; or within 24 hours of last being seen alive.24
Aborted SCD was defined as an appropriate ICD shock for ventricular arrhythmia, successful 
resuscitation following VF or sustained VT causing hemodynamic compromise and requiring 
cardioversion.25 The principal secondary end-point was all-cause mortality. Additional secondary 
end-points were: (i) a composite of cardiovascular (CV) mortality (SCD, HF, stroke or 
thromboembolism), CV hospitalization or cardiac transplantation; and (ii) a HF composite of HF 
death, unplanned HF hospitalization or cardiac transplantation. Death was attributed to HF if
preceded by progressive deterioration in symptoms and signs. HF hospitalization was defined as 
an admission with new or worsening signs and symptoms of HF requiring intensification of HF-
specific treatment.24
Patients were followed-up throughout the study either by postal questionnaire and/or 
telephone interview, through family physicians, clinics and hospital notes. The duration of 
follow-up was calculated from the baseline scan until an end-point occurred or last patient 
contact. Specifically, for the primary end-point, any patients meeting the pre-specified criteria 
for an event were censored from that date. A committee of cardiologists blinded to CMR data 
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adjudicated outcomes (VV, AL, UT, ZK, DA, NP, AV). Deaths were also identified using the UK 
Health and Social Care Information Service to ensure none were missed. The adjudication 
committee established cause of death from death certification, post-mortem results and medical 
records using the ACC/AHA guidance.24 Aborted SCD was confirmed from records including 
ICD electrograms when necessary. 
Statistical Analysis
Baseline characteristics amongst those with and without LGE were compared using the Mann-
Whitney U test for continuous data or Fisher’s exact test for categorical data. Kaplan-Meier 
survival curves were generated and compared using the log-rank test. Event times were measured 
from the baseline CMR date for up to 8 years. The associations between end-points and the 
presence of LGE were analyzed using univariable and multivariable proportional hazard models. 
Results are presented as hazard ratios (HRs) with 95% confidence intervals. The multivariable 
model adjusted for the following covariates: LVEF, NYHA class and age. As part of a sensitivity 
analysis, the univariable model was also adjusted using inverse-probability weighting by a 
propensity score, taking into account a total of 13 baseline co-variates including the presence or 
absence of an ICD, allowing time varying weights for this during follow-up. Details and full 
results of the propensity score analysis can be found in Supplemental Table 1&2 and 
Supplemental Figure 2. In order to examine the dose-response relationship between LGE extent 
and the primary end-point, estimated HRs were calculated for four groups depending on the 
extent of LGE: 1) no LGE; 2) 0-2.5%, 3) 2.5-5% and 4) >5% of total LV mass using univariable 
proportional hazard models. We did not report estimates per 1% increase in LGE because of a 
clear non-linear relationship between LGE extent and the primary end-point. The percentage 
extent of LGE giving the largest c-statistic for the prediction of the primary end-point was 
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calculated from 1000 bootstrap samples. The C-statistic measured the degree to which a model 
can distinguish between cases and controls, taking values between 0.5 and 1.0 with larger values 
indicating better discrimination. In order to estimate the incremental predictive power of LGE 
above and beyond LVEF, a predicted 5-year risk of the primary end-point was calculated from a
Cox proportional model which included LGE and categories of LVEF (40-43%, 44-47%, 48-
51%, 52-55% and 56-59%).  
 For comparison of participants with and without LGE, the sample size was estimated to 
provide greater than 90% power to detect a significant difference in the primary end-point if the 
true hazard ratio was at least 3. Statistical analyses were performed using Stata version 14 
(StatCorp, College Station, TX, USA; SN and JG performed analyses). A p value of <0.05 was 
taken as significant.
Results
At baseline, 424 patients met the inclusion criteria, of which 25 either withheld consent for 
follow-up or had moved abroad (Figure 1).  The report therefore focuses on 399 patients, of 
whom 145 were women, the median LVEF was 50% (IQR:46-54%) and mid-wall LGE was 
present in 25.3%. There was disagreement on the presence of LGE in 8 cases, requiring 
adjudication by a third reviewer. Median follow-up until an event or last contact was 4.6 years
(IQR: 3.5 – 7.0) years.
Baseline characteristics are presented in Table 1. Patients with mid-wall LGE were older 
(p=0.03), more likely to be men (p<0.001), to have diabetes (p=0.015), and to receive loop 
diuretics (p=0.009). They also had lower heart rates (p=0.02) and diastolic blood pressure 
(p=0.02). The most common clinical presentation was with signs or symptoms of HF (n= 176; 
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44.1%). An additional 69 (17.2%) patients presented with symptoms of palpitation secondary to 
atrial arrhythmia or ventricular ectopy, 7 (1.8%) with symptoms of light-headedness or pre-
syncope and 3 (0.8%) with 1st degree AV block or a blunted chronotropic response.  A further 39
(9.8%) patients were diagnosed following referral for family screening. Common indications 
classified as ‘Other’ included diagnostic uncertainty or an abnormal electrocardiogram such as 
the finding of left-bundle branch block.   
 In line with guidelines, an ischemic aetiology was considered in all patients and excluded 
as follows.23 All patients underwent LGE-CMR and those with infarct-patterns of enhancement 
were excluded.23 In addition, 268 (67.1%) patients underwent invasive or computed tomography 
coronary angiography and a further 41 (10.3%) had perfusion imaging (nuclear or CMR) or 
stress echocardiography with no provocation of ischemia. Of the remaining, 60 (15.0%) were 
\HDUVof age without a history of angina or a family history of premature CAD and further 
investigation was deemed unnecessary.  All of the remaining 30 (7.5%) patients were free of 
angina and considered to have a low risk of CAD and in the absence of a class 1 indication, this 
was not performed23. Importantly, none of the patients underwent coronary revascularisation or 
suffered an acute coronary syndrome during the follow-up period.   
Primary End-point - Sudden cardiac death and aborted sudden cardiac death
During follow-up, 18 of 101 patients (17.8%) with LGE reached the primary end-point compared 
to 7 of 299 patients (2.3%) without (HR 9.2; 95% CI 3.9-21.8; P<0.0001) (Figure 2). After 
adjusting for LVEF, NYHA class and age, the presence of LGE predicted SCD and aborted SCD 
(HR 9.3; 95%CI 3.9-22.2; p<0.0001) (Table 2). The results were qualitatively the same 
following adjustment based on the propensity score (Supplemental Table 2). There was little 
evidence of a dose-response relationship between LGE extent and the primary end-point.
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Estimated HRs for patients with a LGE extent of 0-2.5%, 2.5-5% and>5% were 10.6 (95%CI 
3.9-29.4), 4.9 (95% CI 1.3-18.9) and 11.8 (95% CI 4.3-32.3) respectively. In keeping with this 
relationship, the cut-off percentage extent of LGE that provided the largest c-statistic was >0% 
(95% CI: 0.0-8.5; c-statistic: 0.72).
 Overall, 9 of 101 patients (8.9%) with LGE and 6 of 299 (2.0%) without died suddenly 
(HR 4.9; 95% CI 1.8-13.5; p=0.002). Correspondingly, 10 of 101 patients (9.9%) with LGE
compared to 1 out of 299 patients (0.3%) without (HR 34.8; 95% CI 4.6-266.6; p<0.0001) 
suffered aborted SCD. After adjusting for LVEF, NYHA class and age, the presence of LGE
predicted SCD (HR 4.8; 95% CI 1.7-13.8; p=0.003) and aborted SCD (HR 35.9; 95% CI 4.8-
271.4; p<0.001) when analyzed individually (Table 2). The results were qualitatively the same 
following adjustment based on the propensity score (Supplemental Table 2).
The predicted 5-year risk of aborted and actual SCD using a model including both LGE
and LVEF was markedly different to a model using LVEF alone (Figure 3). For example a 
patient with an ejection fraction of 45% had a 5-year predicted risk of 7.8% on the basis of 
LVEF alone, which fell to 3.2% in the absence of LGE but increased to 20.2% if LGE was
present.  
During follow-up, 32 patients (9.0%) had an ICD implanted before the occurrence of the 
primary end-point, 17 of whom also received cardiac resynchronization therapy. Eighteen
patients received ICDs in line with primary prevention guideline recommendations following 
deterioration in LVEF from baseline, 2 following new episodes of sustained VT without 
haemodynamic compromise and 12 outside of conventional guideline recommendations 
following review at multidisciplinary meetings.1, 2 Out of the latter 12 patients, 1  had a 
pathogenic Lamin A/C mutation, 2 had a pacing indication with non-sustained VT (NSVT), 3 
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had NSVT and a family history of SCD, 4 had a history of NSVT alone and 2 presented with 
worsening HF and left bundle branch block and had cardiac resynchronization therapy with a 
defibrillator.  Of 32 patients who received an ICD system, 4 patients (23.5%) with and 0 patients 
(0.0%) without LGE had aborted sudden deaths. Of 367 patients without an ICD system, 9 
patients (10.7%) with and 6 patients (2.1%) without LGE died suddenly.  
Secondary End-points
All-cause mortality
During follow-up, there were 32 deaths, of which 19 were CV and 13 were not (cancer, end-
stage lung-disease, sepsis and acute small bowel obstruction). The overall mortality rate was 
higher in patients with LGE (12.9% vs 6.4%; HR 2.3; 95% CI 1.1-4.6; p=0.02) (Supplemental 
Figure 3). Following adjustment for LVEF, NYHA class and age, a trend towards higher 
mortality in those patients with LGE was noted, however this did not reach statistical 
significance (HR 2.0; 95%CI 1.0-4.1; p=0.056).
Cardiovascular death, hospitalization and transplantation 
There were 19 CV deaths (including 15 SCDs and 3 HF deaths) and 42 unplanned CV 
hospitalizations. Two patients underwent cardiac transplantation, one of whom had full 
histopathological examination of the explanted heart. The gross and microscopic examinations 
correlated with LGE-CMR images (Supplemental Figure 4).   Overall, this composite end-point 
was more common in patients with LGE compared to those without (30.7% vs 10.7%; HR 3.6;
95% CI 2.2-5.8; p<0.0001) (Supplemental Figure 3). After adjusting for LVEF, NYHA class and 
age, the presence of LGE remained an independent predictor of the CV composite end-point (HR 
3.2; 95%CI 1.9-5.4; p<0.0001).  
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Heart failure death, heart failure hospitalization and transplantation 
There were 3 deaths secondary to HF and 18 unplanned HF admissions. The incidence of this 
composite end-point was nominally more common in those with LGE compared to those 
without, although the difference was not statistically significant (7.9% vs 4.4%; HR 1.9; 95% CI 
0.8-4.6; p=0.15) (Supplemental Figure 3). This remained the case following adjustment for 
LVEF, NYHA class and age (HR 1.7; 95% CI 0.7-4.2; p=0.27). 
Discussion
This large study in a population of well-treated and well-characterised DCM patients with mild 
or moderate LV impairment is the first investigation to demonstrate mid-wall LGE on CMR is 
associated with a nine-fold increased risk of SCD and aborted SCD in this select sub-group. 
Importantly, none of the patients within the cohort had a pre-existing indication for ICD 
implantation at baseline, demonstrating the incremental value of LGE-CMR in risk stratification 
in this population.  This focused investigation emphasises the importance of extending risk 
stratification beyond LVEF assessment and extends prior observations in HF populations 
including both ischemic and non-ischemic aetiologies.12, 26 Prediction of SCD and aborted SCD 
was independent of established prognostic variables, including LVEF, NYHA class and age and 
qualitatively the same following adjustment for a large number of covariates based on a 
propensity score.   
International guidelines and statements have highlighted the need to identify those 
patients with an LVEF>35% at highest risk of SCD because the major burden of SCD lies within 
this sub-group and this is currently not accounted for by primary prevention ICD guidelines.3-7
Furthermore, as we move to an era of precision medicine, there is an expanding cohort of 
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patients identified with milder reductions in LVEF in whom optimal therapy remains unclear.27
The DANISH trial has re-emphasised the need to refine our current approaches to risk 
stratification.8 Although, the trial demonstrated a reduction in SCD in patients with severely 
reduced LVEF randomized to ICD implantation, this was not associated with a significant
reduction in all-cause mortality because of high rates of non-sudden cardiac death and non-
cardiac death.8 In other words, in this population of sick patients, ICD therapy simply changed 
the mode of death but not the overall mortality rate. This illustrates the importance of selecting 
patients with a high-risk of SCD and low-risk of non-sudden death who will be exposed to longer 
periods at risk of arrhythmias and may therefore have the most to gain from ICD therapy. Indeed
in sub-group analysis of the DANISH trial, those patients most likely to benefit from ICD 
therapy were those at low risk of non-sudden death, specifically patients <59 years of age and 
those with a NT-pro-BNP<1177pg/ml.8  Patients with mild or moderate reductions in LVEF, not 
only have a low risk of non-sudden death, but are also less likely to have limiting HF symptoms 
compared to those with more severe LV impairment and may therefore have the potential to gain 
a greater number of quality-adjusted life years following an aborted SCD.   Our new data suggest 
a role for LGE-CMR in the identification of patients with less severe left ventricular impairment 
who are at high risk of SCD, low risk of non-sudden death and who may therefore benefit from 
ICD implantation.
In SDWLHQWVZLWKDQ/9()RYHUDPHGLDQIROORZ-up of 4.6 years, the risk of the 
primary end-point in those with mid-wall LGE was 17.8%. In a similarly-designed study with 
marginally longer follow-up (median 5.3 years), the risk of SCD and aborted SCD in all-comer 
'&0SDWLHQWVZLWKDQ/9()ZDVLQFUHDVLQJWRLQWKHVXEJURXSZLWKLGE,
but dropping to only 11.1% in those without LGE.9 We have therefore observed an
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approximately equivalent UDWHRI6&'HYHQWVLQSDWLHQWVZLWKDQ/9()DQGLGE compared 
to all WKRVHZLWKDQ/9()This observation provides support for the CMR-Guide 
(NCT01918215) randomized trial which aims to evaluate the benefit of ICD therapy in patients 
with LVEF 36-50% and LGE. 
The greatest increment in SCD risk occurred between patients with no LGE and those 
with the smallest extent (0-2.5%). This was confirmed by analysis of Harrell’s C Statistic which 
demonstrated a LGE extent cut-off of >0% as the best discriminator of event-free survival time. 
The lack of a linear dose-response relationship between the extent of LGE and the primary end-
point is novel and suggests that binary risk models based on the presence or absence of LGE are 
appropriate rather than models that examine risk based on the extent of LGE which assume 
linearity.9, 16   
 Myocardial fibrosis is a widely accepted substrate for ventricular arrhythmia, supporting 
the biological plausibility of the findings. An electro-mapping study in patients with DCM 
demonstrated LGE in all patients with inducible VT or a history of sustained VT and mapped the 
arrhythmia to the corresponding location.28 Additionally, areas of fibrosis interacting with 
channels of healthy myocardium in the peripheral ‘heterogeneous zone’ of the scar have been 
associated with re-entry wavefronts and targeting of these at catheter ablation reduces VT.29-32 It 
is therefore conceivable that the surface area of the ‘gray-zone’ between scar and healthy tissue 
determines the risk of VT, rather than the mass of the scar, explaining the lack of a dose-
dependent association between LGE extent and SCD events in our study.17, 18   
Limitations
This study was performed in a single, large-volume, experienced center. While this enables the 
use of a standardized protocol and scan interpretation from the same independent operators, it 
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introduces the possibility of referral bias. We do, however, report similar baseline characteristics 
to other registries.13, 33  Moreover, the referral base is broad, from specialist and non-specialist 
centers and we report a range of common indications for the scan. Data from 193 of 399 patients 
were included in an earlier investigation on ‘all-comers’ with DCM.9 These patients had 
extended follow-up in this study which is unique in examining a focused clinical question in a 
targeted population using an alternative pre-specified primary end-point in order to address an 
unmet clinical need.
We also recognise the modest number of events in the study. We specified strict criteria 
for the primary end-point, excluding appropriate ATP, in order to generate the most clinically 
meaningful data. Within this large study, we have identified a strong predictor of clinically 
important events responsible for a major burden of SCD in the DCM population.  Based on the 
event rates in this study, a randomized trial of defibrillator therapy versus medical therapy in 
patients with a LVEF>40% and mid-wall LGE followed-up for 5 years would require 971 
patients to have 80% power to detect a difference in all-cause mortality, at a significance level of 
5%, assuming a 60% reduction in SCD with the intervention. This is comparable to the sample 
size of other large device trials.8  
 In this study, CAD was not excluded in all cases by coronary angiography. However, 
LGE-CMR has been shown to be as accurate in the diagnosis of the aetiology of HF. 23 In 
DGGLWLRQWKHPDMRULW\RISDWLHQWVZKRGLGQRWXQGHUJRFRURQDU\DQJLRJUDSK\ZHUH\HDUVRI
age without a history of angina or a family history of premature CAD.  Only 30 patients, all 
without a history of angina, were aged over 40 and had no additional investigations to exclude 
CAD. None of the patients suffered an acute coronary syndrome or had coronary 
revascularisation during the study. Whilst we accept that CAD cannot be definitively excluded in 
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this small group, significant CAD is nevertheless unlikely. The small size of this group means 
that this is unlikely to have biased the data to a significant extent. 
ICD implantation was more frequent in patients with LGE; however our results were 
consistent after adjusting for this as part of the propensity score analysis (Supplemental Table 2). 
Whilst it is possible that the higher rate of ICD implantation reflects selection bias, the presence 
of LGE was not cited as an indication for implantation in any case. Amongst patients who had an 
ICD implanted, the rate of aborted SCD was higher in those with LGE compared to those 
without. Furthermore, despite the higher rate of ICD implantation in those with LGE, these 
patients had a higher rate of SCD. We acknowledge the limitations of aborted SCD as an end-
point and recognise that a proportion of arrhythmias resulting in appropriate shocks may have 
terminated spontaneously. However, our data on the association with SCD adds robustness. We 
also recognise that a proportion of SCDs may relate to aneurysmal rupture and cerebral 
haemorrhage, however, in the absence of a biologically plausible link between LGE and these 
events, the effect of this would be to dilute the association between LGE and SCD rather than to 
enhance it. ICD programming was at the discretion of the individual units. We did not routinely 
measure B-type natriuretic peptide but we have included alternative variables which strongly 
predict prognosis in HF, such as LAVi and NYHA class. Contemporary CMR techniques such as 
T1-mapping were not available at the outset but we note a lack of consistency in the findings of 
other studies investigating its role in outcome prediction, with little evidence of incremental 
value in addition to LGE.34, 35
Conclusions 
For the first time, we demonstrate that in patients with DCM and mild or moderate left 
ventricular systolic impairment, who do not meet conventional criteria for an ICD, the presence 
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of mid-wall LGE identifies a sub-group at high-risk of SCD.  The risk of SCD in this sub-group 
was comparable to that seen in all-comer patients with a LVEF<35%, and importantly  their risk 
of non-sudden cardiac death was low, suggesting that ICD therapy may have the potential to 
reduce all-cause mortality and extend ‘quality life’. 
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Table 1. Baseline demographics for patients based on the presence or absence of mid-wall LGE   
Midwall LGE
All Patients (n=399) No (n=298) Yes (n=101) p
Age (years) 49.9 (15.3) 48.9 (15.5) 53.0 (14.2) 0.030
Male 254 (63.7) 175 (58.7) 79 (78.2) <0.001 
BSA (m2) 1.96 (0.24) 1.95 (0.24) 1.98 (0.22) 0.11
Heart Rate (bpm) 69.8 (13.0) 70.7 (13.3) 67.3 (11.8) 0.020
Systolic blood pressure (mmHg) 122.7 (16.3) 123.4 (16.5) 120.8 (15.5) 0.22
Diastolic blood pressure (mmHg) 72.9 (9.9) 73.5 (9.8) 71.0 (10.2) 0.018
Atrial Fibrillation / Flutter 64 (16.0) 49 (16.4) 15 (14.9) 0.76
Hypertension 81 (20.3) 56 (18.8) 25 (24.8) 0.20
Diabetes 25 (6.3) 13 (4.4) 12 (11.9) 0.015
Hypercholesterolemia 74 (18.5) 55 (18.5) 19 (18.8) 1.00
Current Smoker 62 (15.5) 47 (15.8) 15 (14.9) 0.88
Excess Alcohol 33 (8.3) 25 (8.4) 8 (7.9) 1.00
Family History of DCM 51 (12.8) 35 (11.7) 16 (15.8) 0.30
Family History of SCD 36 (9.0) 26 (8.7) 10 (9.9) 0.69
Left bundle branch block 103 (25.8) 81 (27.2) 22 (21.8) 0.36
Medications     
Beta-blocker 259 (64.9) 187 (62.8) 72 (71.3) 0.15
ACE Inhibitor 268 (67.2) 193 (64.8) 75 (74.3) 0.087
ARB 80 (20.1) 61 (20.5) 19 (18.8) 0.78
Loop Diuretic 91 (22.8) 58 (19.5) 33 (32.7) 0.009
Aldosterone Inhibitor 78 (19.6) 58 (19.5) 20 (19.8) 1.00
Scan indication     
HF 176 (44.1) 132 (44.3) 44 (43.6)
0.50
Palpitations & presyncope 79 (19.8) 54 (18.1) 25 (24.8)
Family Screening 39 (9.8) 30 (10.1) 9 (8.9)
Other 105 (26.3) 82 (27.5) 23 (22.8)
NYHA     
I 228 (57.3) 170 (57.2) 58 (57.4)
0.36II
144 (36.2) 110 (37.0) 34 (33.7)
III 25 (6.3) 17 (5.7) 8 (7.9)
IV 1 (0.3) 0 (0.0) 1 (1.0)
CMR parameters     
LVEDVi 111.1 (19.4) 110.0 (18.2) 114.2 (22.4) 0.16
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LVESVi 56.1 (13.0) 55.3 (12.0) 58.6 (15.2) 0.072
LVEF (%) 49.6 (4.9) 49.9 (4.9) 49.0 (4.9) 0.11
LV Mass Index (g/m2) 86.0 (22.5) 85.0 (24.0) 89.0 (17.2) 0.007
RVEDVi 88.6 (20.3) 87.7 (20.1) 91.0 (20.8) 0.15
RVESVi 38.9 (14.7) 38.3 (14.3) 40.8 (15.6) 0.13
RVEF (%) 57.4 (9.4) 57.8 (9.2) 56.1 (9.7) 0.15
LAVi 58.3 (22.6) 57.3 (22.3) 61.1 (23.4) 0.079
(ACE – angiotensin converting enzyme, ARB – angiotensin II receptor blocker, CMR – cardiovascular magnetic 
resonance, DCM – dilated cardiomyopathy, LAVi – indexed left atrial volume, LVEDVi – indexed left ventricular 
end-diastolic volume, LVEF – left ventricular ejection fraction, LVESVi – indexed left ventricular end-systolic 
volume, MRA – mineralocorticoid antagonist, RVEDVi – indexed right ventricular end-diastolic volume, RVEF –
right ventricular ejection fraction, RVESVi – indexed right ventricular end-systolic volume, SCD – sudden cardiac 
death, SD – standard deviation, VT – ventricular tachycardia, VF - ventricular fibrillation)
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Table 2. Univariable and multivariable analyses for the primary end-point
Outcome LGE status Events  n (%)
Univariable Multivariable*
HR (95% CI) P Value HR (95% CI) P Value
SCD or Aborted SCD LGE -
7 (2.3)
9.2 (3.9, 21.8) <0.0001 9.3 (3.9, 22.3) <0.0001
LGE + 18 (17.8)
SCD LGE - 6 (2.0) 4.9 (1.8, 13.5) 0.002 4.8 (1.7, 13.8) 0.003 
LGE + 9 (8.9)
Aborted SCD LGE -
1 (0.3)
34.8 (4.6, 266.6) <0.0001 35.9 (4.8, 271.4) <0.001 
LGE + 10 (9.9)
Analysis is included for end-point components individually. (*adjusted for left ventricular ejection 
fraction, New York Heart Association Class and age; CI – confidence intervals, IPW: inverse probability 
weighting, LGE+ – late gadolinium enhancement present, LGE- - late gadolinium enhancement absent; 
SCD – sudden cardiac death)
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Figure Legends
Figure 1. Identification of the study population.
Flow chart detailing the identification, inclusion and exclusion of patients. (CAD – coronary 
artery disease; LVEDV – left ventricular end-diastolic volume, LVEF – left ventricular ejection 
fraction, LGE – late gadolinium enhancement)
Figure 2. Primary end-point survival analysis 
Kaplan-Meier curve of the time to first event for the primary end-point by presence (red-line) or 
absence (blue line) of mid-wall LGE.   
Figure 3. 5-year risk estimates of the primary end-point
5-year risk estimates for primary end-point based on left ventricular ejection fraction (LVEF) 
alone (green line) and mid-wall LGE status in addition to LVEF (red line – presence of LGE,
blue line – absence of LGE).  (LGE – late gadolinium enhancement; LVEF – left ventricular 
ejection fraction)
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SUPPLEMENTAL MATERIAL 
Supplemental Methods 
CMR protocol 
Steady-state free-precession sequences were used to acquire cine images in standard long axis 
planes and in contiguous short axis slices from the atrioventricular ring to the apex. Intravenous 
gadopentetate dimeglumine or gadobutrol (Schering, Berlin, Germany) were used at a dose of 
0.1mmol/kg.  An inversion recovery gradient echo sequence was used to obtain LGE images, ten 
minutes after gadolinium administration, in identical planes to the cine images, in two phase-
encoding directions. Inversion times were optimized to null the myocardium. Ventricular volumes 
and mass were calculated using dedicated software (CMRtools, Cardiovascular Imaging Solutions, 
London, UK). Left atrial volumes indexed to body surface area (LAVi) were measured using the 
biplane area-length method1.  
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Supplemental Primary End-point Analysis  
We report the primary end-point analyses for those patients meeting the inclusion criteria set out in 
the main manuscript and in addition, those patients with a prior history of ventricular fibrillation, 
ventricular tachycardia and syncope, excluded from the analysis in the main manuscript. Overall, 432 
pateints were followed-up for a median of 4.5 (IQR: 3.4 – 6.6) years, of whom 159 were women, the 
median LVEF was 50% (IQR:46-54%) and mid-wall LGE was present in 25.7%. 
During follow-up, 21 of 111 patients (18.9%) with LGE reached the primary end-point compared to 
11 of 321 patients (3.4%) without (HR 6.5; 95% CI 3.2-13.5; P<0.0001) (Figure A).  After adjusting for 
LVEF, NYHA class, age and gender the presence of LGE predicted SCD and aborted SCD (HR 7.6; 
95%CI 3.3-17.4; p<0.0001).  
Overall, 9 of 111 patients (8.1%) with and 7 of 321 patients (2.2%) without fibrosis died suddenly (HR 
4.1; 95% CI 1.6-10.9; p=0.004). Correspondingly, 13 of 111 patients (11.7%) with fibrosis compared 
to 4 out of 321 patients (1.2%) without (HR 10.7; 95% CI 3.5-32.9; p<0.0001) suffered aborted SCD. 
Following adjustment, the presence of fibrosis predicted SCD (HR 3.5; 95% CI 1.1-10.8; p=0.03) and 
aborted SCD (HR 14.6; 95% CI 4.7-46.2; p<0.001) when analyzed individually.   
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Supplemental Tables 
Supplemental Table 1. Propensity score model 
  OR (95% CI) p 
LVEF (per 10) 0.94 (0.54, 1.62) 0.82 
Age (per 10) 1.14 (0.94, 1.37) 0.18 
Male 2.46 (1.34, 4.49) 0.003 
LAVi (per 10) 1.01 (0.89, 1.15) 0.83 
NYHA II 0.97 (0.54, 1.73) 
0.55 
NYHA III / IV 1.74 (0.61, 4.97) 
LVEDVi (per 10) 1.06 (0.90, 1.24) 0.50 
RVEF (per 10) 0.94 (0.66, 1.33) 0.72 
ACE Inhibitor 1.30 (0.74, 2.30) 0.36 
Beta Blocker 1.34 (0.75, 2.37) 0.32 
Diabetes 2.65 (1.06, 6.62) 0.037 
HR (per 10) 0.89 (0.72, 1.09) 0.26 
Scan Indication     
Heart Failure 1.00 
0.24 
Palpitation /  Presyncope 1.29 (0.68, 2.45) 
Family Screening 1.50 (0.61, 3.68) 
Other 0.68 (0.35, 1.32) 
ICD Implant 3.31 (1.67, 6.58) <0.001 
 
Baseline covariates used to construct the propensity score model were as follows: LVEF, NYHA class, 
age, gender, LAVi, LVEDVi, RVEF, ACE inhibitor and beta-blocker prescription, heart rate, scan 
indication and history of diabetes mellitus.  ICD implantation was also included, allowing time-
varying weights during follow-up. 
(ACE – angiotensin converting enzyme, ARB – angiotensin II receptor blocker, HR – heart rate, LAVi – 
indexed left atrial volume, LVEDVi – indexed left ventricular end-diastolic volume, LVEF – left 
ventricular ejection fraction, RVEF –right ventricular ejection fraction, VT – ventricular tachycardia, 
VF - ventricular fibrillation) 
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Supplemental Table 2. Results of the Propensity score analysis 
Outcome LGE Status Events n (%) 
IPW Estimate 
HR (95% CI) P Value 
SCD or Aborted SCD 
LGE - 7 (2.3) 
8.0 (3.3, 19.5) <0.0001 
LGE + 18 (17.8) 
SCD   
LGE- 6 (2.0) 
4.6 (1.6, 13.1) 0.005 
LGE+ 9 (8.9) 
Aborted SCD 
LGE- 1 (0.3) 
32.9 (4.3, 249.9) <0.001 
LGE+ 10 (9.9) 
All-Cause Mortality 
LGE- 19 (6.4) 
2.0 (0.9, 4.2) 0.086 
LGE+ 13 (12.9) 
HF Death, Hospitalisation or 
Transplant 
LGE- 13 (4.4) 
1.6 (0.6, 4.4) 0.32 
LGE+ 8 (7.9) 
CV Death, Hospitalisation or 
Transplant 
LGE- 32 (10.7) 
3.1 (1.8, 5.4) <0.0001 
LGE+ 31 (30.7) 
 
Inverse probability weighting analyses for the primary and secondary end-points. (weights based on 
left and right ventricular ejection fraction, indexed left ventricular end-diastolic volume, New York 
Heart Association Class, age, gender, indexed left atrial volume, ACE inhibitor and beta-blocker 
prescription, heart rate, scan indication, history of diabetes mellitus and the presence or absence of 
an ICD allowing time carrying weights for the latter; CI – confidence intervals, CV – cardiovascular, 
HF – heart failure, IPW: inverse probability weighting, LGE+ – late gadolinium enhancement present, 
LGE- - late gadolinium enhancement absent; OR – odds ratio; SCD – sudden cardiac death) 
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Supplemental Figures & Figure Legends 
Supplemental Figure 1. Supplemental primary end-point analysis 
 
Kaplan-Meier curves of the time to first event for the primary end-points by presence (red-line) or 
absence (blue line) of mid-wall LGE, including patients with a prior history of sustained ventricular 
tachycardia, ventricular fibrillation or syncope. 
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Supplemental Figure 2. Histogram of the propensity score distribution in the groups with and 
without LGE 
 
 
(LGE – late gadolinium enhancement) 
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Supplemental Figure 3. Secondary end-points 
 
Kaplan-Meier curves of the time to first event for the secondary end-points by presence (red-line) or 
absence (blue line) of mid-wall LGE.   
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Supplemental Figure 4. Histological correlation 
 
A: Pre-transplant late gadolinium enhancement (LGE) cardiovascular magnetic resonance 
demonstrating extensive mid-wall and sub-epicardial LGE, including the septum at mid-ventricular 
level. B: Post-transplant gross examination of a short-axis slice at mid-ventricular level confirming 
extensive mid-wall replacement fibrosis. C: Post-transplant micrscopic examination of a specimen 
from the septum of the explanted left ventricle, at x300 magnification, confirming replacement 
(arrow) and pericellular fibrosis. 
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